AstraZeneca Pharma India Limited (BOM:506820)
India · Delayed Price · Currency is INR 8,596.15
-103.45 (-1.19%)
At close: Mar 5, 2026
AstraZeneca Pharma India Employees
AstraZeneca Pharma India had 600 employees as of December 31, 2025. The number of employees decreased by 20 or -3.23% compared to the same quarter last year.
Employees
600
Change
-20
Growth
-3.23%
Revenue / Employee
36.29M INR
Profits / Employee
3.35M INR
Market Cap
214.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 600 | -20 | -3.23% |
| Sep 30, 2025 | 600 | -200 | -25.00% |
| Jun 30, 2025 | 600 | -300 | -33.33% |
| Mar 31, 2025 | 802 | -138 | -14.68% |
| Dec 31, 2024 | 620 | -320 | -34.04% |
| Sep 30, 2024 | 800 | - | - |
| Jun 30, 2024 | 900 | -47 | -4.96% |
| Mar 31, 2024 | 940 | -7 | -0.74% |
| Mar 31, 2023 | 947 | -236 | -19.95% |
| Mar 31, 2022 | 1,183 | -100 | -7.79% |
| Mar 31, 2021 | 1,283 | -42 | -3.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jubilant Pharmova | 5,547 |
| J. B. Chemicals & Pharmaceuticals | 5,304 |
| CORONA Remedies | 4,500 |
| Granules India | 4,066 |
| Caplin Point Laboratories | 3,966 |
| Abbott India | 3,659 |
| GlaxoSmithKline Pharmaceuticals | 3,113 |
| Procter & Gamble Health | 1,326 |
AstraZeneca Pharma India News
- 22 days ago - ASTRAZEN shares fall over 4% as Q3 EBITDA drops 41.8% YoY to Rs 44.8 crore - Business Upturn
- 23 days ago - Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment - NDTV
- 2 months ago - AstraZeneca Pharma India receives CDSCO approval to import and market Datverzo in India - Business Upturn
- 3 months ago - AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India - Business Upturn
- 3 months ago - AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India - Business Upturn
- 5 months ago - AstraZeneca Pharma India to launch hyperkalemia treatment ‘Lokelma’ in November 2025 - Business Upturn
- 5 months ago - AstraZeneca Pharma India secures CDSCO approval for additional indication of Enhertu - Business Upturn
- 6 months ago - AstraZeneca Pharma receives Rs 60.49 crore NPPA show cause notice over Symbicort pricing - Business Upturn